Company: PFSA
Filing Date: 2025-04-28
Form Type: S-4/A
Source: 0001213900-25-035718
Chunk: 499

Company: Profusa, Inc.
Filing Date: 2025-04-28
Form: S-4/A
Chunk 499
---
 pursuant to Rule 144 without registration one year after we have completed our initial business combination. 291

MANAGEMENT OF NEW PROFUSA AFTER THE BUSINESS COMBINATION References in this section to “we”, “our”, “us” and the “Company” generally refer to Profusa, prior to the Business Combination and New Profusa and its consolidated subsidiaries after giving effect to the Business Combination. Management and Board of Directors The following table sets forth the persons NorthView and Profusa anticipate will become the directors and executive officers of New Profusa.

| Name                              |     | Age |     | Position                                       |
| Directors and Executive Officers: |     |     |     |                                                |
| Ben C. Hwang, Ph.D.               |     |  57 |     | Chairman of the Board; Chief Executive Officer |
| Fred Knechtel                     |     |  64 |     | Chief Financial Officer                        |
| Rajesh Asorpota                   |     |  56 |     | Director                                       |
| Lauren Chung                      |     |  48 |     | Director                                       |
| Peter O’Rourke                    |     |  52 |     | Lead Independent Director                      |
| Jack Stover                       |     |  71 |     | Director                                       |

A description of the business experience of Ben C. Hwang, Ph.D., is provided above under the heading “Management of Profusa — Executive Officers.” A description of the business experience of Fred Knechtel, Lauren Chung, Peter O’Rourke, and Jack Stover, is provided above under the heading “Information about Northview — Directors and Executive Officers.” Rajesh Asarpota— Mr. Asarpota is currently the chief financial officer at Augmedics, a company that has pioneered cutting -edgeaugmented reality technologies to improve surgical outcomes for spine surgery. Prior to Augmedics, from September 2020 to October 2021, he served at ApiJect as executive vice president, chief financial officer and head of technology. ApiJect is a medical technology company that seeks to revolutionize how medicines and vaccines are filled, finished and delivered. Prior to ApiJect, from August 2017 to September 2020, Asarpota served as executive vice president and chief financial officer with NuVasive, a global public company and leader in minimally invasive, procedurally integrated spine solutions. Prior to NuVasive, he spent two years in the private equity space at Imaging Advantage and Cole Parmer as executive